Objective: The evidence of 2nd line chemotherapy has not been validated. We investigated the treatment outcomes of 2nd line palliative chemotherapy in patients with biliary tract cancer (BTC) and analyzed the factors affecting response or survival. Methods: We retrospectively reviewed and analyzed the outcomes in advanced BTC patients who underwent 2nd line chemotherapy in Soonchunhyang Universitiy Hospitals (Bucheon, Seoul, and Cheonan). Results: From December 2004 to May 2014, 65 patients were enrolled. The median age was 56 years (range, 40 to 76 years) and the ratio of cholangiocarcinoma (intrahepatic or extrahepatic), gall bladder cancer, and ampulla of Vater cancer was 41 (63.1%):18 (27.7%):6 (9.25%). Half of the patients (33 patients, 50.8%) were treated with gemcitabine-based and 28 patients (43.1%) with 5-fluorouracil-based therapy. The response rate was 3.0% and disease control rate was 21.5% in intention-to-treat analysis. Median overall survival (OS) was 7.2 months (95% confidence interval [CI], 3.9 to 10.5 months) and median progression free survival (PFS) was 3.7 months (95% CI, 2.5 to 4.9 months). In multivariate analysis, patients with good performance status (PS) (P= 0.001) and chemo-sensitive tumor to 2nd line chemotherapy (P = 0.000) had longer PFS as compared to the others. In addition, patients with good PS (P= 0.003), chemo-sensitive tumor to 1st line (P= 0.046), and 2nd line chemotherapy (P= 0.004) were good prognostic factors for OS.
INTRODUCTION
Biliary tract cancer (BTC) is generally rare in Western countries but common in Korea where approximately 5,130 new patients were diagnosed in 2012 [1] . Treatment of BTC is limited, and although surgery provides the only curative treatment, most patients are not eligible for surgery because of advanced stage at diagnosis or combined impaired liver function. Therefore, there is a need for palliative chemotherapy for inoperable BTC patients. Previous study demonstrated an improvement of overall survival (OS) and quality of life for patients receiving chemotherapy versus best supportive care [2, 3] . In addition, gemcitabine-cisplatin combination was identified as the new standard 1st-line therapy in advanced BTC [4] as compared to gemcitabine monotherapy. In this phase III study, the median progression free survival (PFS) was 8.5 months as compared to the approximately 4-6 months in other phase II studies [5] [6] [7] . At the time of failure to 1st line therapy, some patients who were able to maintain good performance status (PS) went into salvage therapy. There is a need to develop salvage chemotherapy to improve the outcome of advanced BTC. However, 2nd line therapy has not validated as compared to the many efforts to improve front line therapy in BTC patients. Randomized trial is difficult due to the rarity of the tumor with progression to 1st line therapy. Therefore, we investigated the treatment outcomes such as the effect and toxicities of 2nd line palliative chemotherapy in BTC patients and evaluated factors affecting response or survival. 
Treatment efficacy and toxicities of 2nd line chemotherapy
Among 65 patients, most had undertaken gemcitabine-based (gemcitabine alone, gemcitabine/cisplatin, gemcitabine/oxaliplatin; n = 33; 50.8%) and 5FU-based chemotherapy (5FU/cisplatin, 5FU/leucovorin, 5FU/leucovorin/oxaliplatin, oral 5FU alone; n= 29; 44.6%). Few others (n= 3, 4.6%) were treated with anthracyline or bevacizumab combination. Response evaluation was done in 54 patients. Two of 65 patients had a PR to 2nd line chemotherapy and 12 patients (18.5%) had SD. In ITT analysis, overall response rate (ORR) and DCR were calculated as 3.0% and 21.5%, respectively ( Table 2 ). Median overall OS was 7.2 months (95% CI, 3.9 to 10.5 months) and median PFS was 3.7 months (95% CI, 2.5 to 4.9 months) ( Fig. 1 ).
Treatment related toxicities were assessable in all patients (Table 3) .
Adverse events during treatment were predominately grade (Gr) 1-2, except for neutropenia. Among hematologic toxicities, Gr 3-4 neutropenia was detected in 24 patients (36.9%), but only 3 patients experienced neutropenic fever. Gr 3-4 anemia and thrombocytopenia were developed in 9 patients (13.85) and 13 patients (20.0%),
respectively. Most of non-hematologic toxicities were Gr 1-2. Severe Gr 3-4 non-hematologic toxicities were anorexia, fatigue, emesis, stomatitis, and diarrhea in 5 cases (7.7%), 4 cases (6.2%), 2 cases (3.1%), and 2 cases (3.1%), respectively.
Prognostic factors
Among the types of 2nd line therapy, sex, age, primary tumor site, disease pattern, carbohydrate antigen 19-9 value, efficacy to the 1st line therapy, ECOG PS, albumin level, and eGFR, none was a significant factor on the effect of the 2nd line therapy (Table 4) . Values are presented as number (%), unless otherwise stated. ITT, intention to treat. Values are presented as number (%). This value was analyzed by Kaplan-Meier method through SPSS ver. 14.0 (SPSS Inc., Chicago, IL, USA).
The patients with good PS, chemo-sensitive tumor to 1st line, or 2nd line chemotherapy were good prognostic factor of OS in univariate analysis ( Fig. 2A-C) . The ECOG PS and efficacy to 2nd line chemotherapy were also good prognostic factors to PFS in univariate analysis (Table 5 , Fig. 2D ).
In multivariate analysis, patients with good PS (P = 0.001) and chemo-sensitive tumor to 2nd line chemotherapy (P = 0.000) had longer PFS as compared to the others (Table 6 ). In addition, good PS status (P = 0.003), chemo-sensitive tumor to 1st line (P = 0.046), and 2nd line chemotherapy (P = 0.004) were good prognostic factors for OS (Table 6) .
DISCUSSION
BTC is a highly lethal tumor and the prognosis of patients with advanced BTC is poor. The survival benefit of chemotherapy over best supportive care for advanced BTC was initially suggested in a phase III trial on advanced pancreatic and biliary tract cancers [2] .
There have been many phase II studies for 1st line chemotherapy in patients with advanced BTC [5] [6] [7] and the results of a pooled analysis of 104 trials that included 2,810 patients with advanced BTC showed that response rates and tumor control were higher for the subgroup of patients receiving a combination of gemcitabine and platinum based agents [8] . In an advanced biliary cancer (ABC)-02 study, which enrolled 410 patients with advanced BTC, the combination of gemcitabine and cisplatin improved OS and PFS by 30% over gemcitabine alone [4] . Based on this phase III study, gemcitabine plus cisplatin combination chemotherapy has also become the accepted standard therapy in advanced BTC in In case of 5FU-based therapy in 1st line therapy, phase II study of salvage therapy with gemcitabine was reported by Oh et al. [9] . In the 29 patients, an ORR of 6.9%, median time to progression of 1.6 months, and median OS of 4.1 months was reported. In case of gemcitabine-based therapy in 1st line therapy, phase II study of salvage therapy was done with S-1 based [10, 11] , FAM (5FU, adriamycin and mitomycin) [12] , or capecitabine based therapy [13] . Less than 10% of response rate was noticed and less than 7 months of OS was reported, with the exception of a report by Sasaki et al. [11] .
The benefit of 2nd line chemotherapy in BTC as compared to best supportive care (BSC) has not yet been confirmed. In an ABC-02 study [4] , 15.3% BTC patients were treated with 2nd line chemotherapy, while 75% total patients received 2nd line chemotherapy in the BT-22 study [14] . However, the median OS of the 2 large studies were similar at approximately 11 months (11.7 months vs. This value was analyzed by Cox's proportional hazard regression model through SPSS ver. 14.0 (SPSS Inc., Chicago, IL, USA).
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months)
. Thus, BSC is the standard of care so far.
The ABC-06 trial is a phase III randomized trial to determine whether patients with advanced BTC benefit from the addition of mFOLFOX chemotherapy over active symptom control in the 2nd line setting, after progression of 1st line treatment with gemcitabine and cisplatin. It will be the first randomized phase III in the 2nd line setting. We expect that the benefit of 2nd line therapy in advanced biliary tract cancer could be demonstrated in this study.
In a recent review on 2nd line chemotherapy by Lamarca et al.
[15] that included 25 studies of 761 patients, the mean OS was 7.2 months and PFS was 3.2 months, with RR 7.7% and DCR 49.5%.
The result was similar to our study, but the RR or DCR in our report was inferior to the Lamarca's report. In our study, 11 patients
were not evaluated for chemo-response, therefore, the factors of ITT analysis with retrospective study may result in an inferior response rate as compared to Lamarcar's results. In addition, ECOG PS 2-3 patients were 35.4% of the total patients in our study population and recurrent or metastatic disease were 81.5%. These unfavorable factors may have affected poor outcomes as compared to other studies. We found a modest effect of 2nd line chemotherapy based on literature review and our report.
We analyzed several factors by univariate and multivariate analysis to determine affecting and prognostic factors to chemo-response and survival. We identified no significant factors affecting the chemo-response in 2nd line chemotherapy.
In multivariate analysis, the patients with good PS status (P = 0.001) and chemo-sensitive tumor to 2nd line chemotherapy (P = 0.000) had longer PFS as compared to others. In addition, patients with good PS status (P = 0.003), chemo-sensitive tumor to 1st line (P = 0.046), and chemo-sensitive tumor to 2nd line chemotherapy (P = 0.004) were good prognostic factors for OS. Other prognostic factors such as albumin level reported by Oh et al. [9] ' report or doublet regimen type recognized by Walter et al. [16] were not significant in the current study. Patients with good PS were confirmed as good prognostic factors to PFS or OS in our study as well as earlier studies.
Based on these results, we suggest that patients with poor PS should not be offered 2nd line chemotherapy. Patients with good PS and chemo-sensitive in 1st line may be considered as candidates for 2nd line chemotherapy.
Novel agents that target anti-angiogenic or eGFR/Her2/RAS/ RAF pathway inhibitors have been tested mainly in 1st line, alone, or in combination with cytotoxic chemotherapy, however, the outcomes have been disappointing so far. Cetuximab was tested as combination regimen with gemcitabine and oxaliplatin in the 1st line setting, however the randomized phase II trial did not demonstrate the additional effect of cetuximab [17] . Some agents such as MEK inhibitor, selumetinib, or the combination of bevacizumab-erlotinib are possible effective drugs in 1st or 2nd line setting as reported on phase II study [18, 19] . However, further investigation with novel targeting agent is needed for advanced BTC.
Our study was a retrospective study with a small number of patients. Therefore, there is limitation to the interpretation of the results. However, we found that outcomes of the 2nd line chemotherapy in patients with advanced BTC and prognostic factors.
Our results indicated that prospective study on advanced biliary tract cancer with good PS and chemo-sensitive tumor for 2nd line chemotherapy is warranted.
